Mike, like this?.....tell me again how ARYC and ARRAYIT should be kept separate while this one? Arrayit and COVID-19 Testing + additional company info below.
President Trump's team: “We really want a fingerpick type assay”
Dr. Anthony S. Fauci, Director of Allergy and Infectious Disease (NIAID)
..."We must not confuse Allergy symptoms with COVID-19 flu symptoms. We’re in high pollen season trigering Allergies - causing congestion, Rhinitis (runny nose) and Aerophagia (mouth breathing) leading to bacterial sore throat and fever. These symptoms together present as flu and may symptomatically be confused with COVID-19. It’s important we eliminate Allergy as a cause of these symptoms when diagnosing for COVID-19... (paraphrased)"
The science behind how Arrayit tests for COVID-19:
Sensors (Basel). 2017 Sep; 17(9): 2157. Published online 2017 Sep 20. doi: 10.3390/s17092157 PMCID: PMC5621023 PMID: 28930175 Sensitive Genotyping of Foodborne-Associated Human Noroviruses and Hepatitis A Virus Using an Array-Based Platform Beatriz Quiñones,1,* Bertram G. Lee,1 Todd J. Martinsky,2 Jaszemyn C. Yambao,1 Paul K. Haje,2 and Mark Schena2
Arrayit is now a Medicare in-network provider. Offering one-of-a-kind Allergy Testing that's fast, convenient and most importantly, billable. Review the data that supports this success, and leverage this success for your own clinic.”
Extra on Arrayit: Arrayit recently completed an allergy testing pilot program for a top retail chain, established a nationwide network of 1,700 allergy sales professionals, met with top officials at the United States Food and Drug Administration (FDA) regarding approval of a major product line, fulfilled an FDA clinical instrumentation contract, received approval for in-store promotions by a major retailer, announced allergy testing partnerships with major allergy therapeutics providers, received approval for direct Medicare billing and electronic Medicare reimbursement from the Centers for Medicare and Medicaid Services, launched the Patient Data Solutions allergy portal for doctors and clinics, celebrated 25 years of company operations, announced an allergy testing services agreement with a major health and wellness provider, provided a letter to shareholders from the company's Chief Executive Officer, received endorsement by First Pediatrics Medical Group, announced in-network allergy testing services contracting with a top five commercial health benefits company, doubled its weekly billing guidance to $2 million per week, appointed an Apple enterprise healthcare partner to accelerate revenues and earnings growth, expanded allergy testing services evaluation with a major retail pharmacy chain, grew its allergy testing healthcare network to more than 700 clinics, retained a top credentialing company to accelerate commercial and government payor reimbursement, aced five consecutive rounds of proficiency testing with a top proficiency testing leader, signed an in-network allergy testing services agreement with a major California-based health benefits company, received a certificate of deemed status into 2020 from the California Department of Public Health and expanded its clinic network in Hawaii. Philippines test revenues and earnings will be reported in the company's upcoming audited quarterly and annual financial statements.
https://www.twinarborlabs.com “Cutting Edge Technology. Twin Arbor Analytical utilizes cutting edge technologies such as Arrayit’s (ARYC) proprietary microarray platform. This system was developed as a research cooperative agreement with the United States Department of Agriculture – Agricultural Research Services (USDA-ARS) as a low-cost high throughput system for the analysis of microbial contaminants such as E. coli, salmonella, listeria, Noro virus and Hepatitis A” Some Marketing partners for allergy testing: https://lhkv.avtosvet.pro/food/5177-allergy.php https://www.nationwideallergy.net/ https://birddogpharma.com/allergy-services/
Aspects of the inventions described herein have been described on the website of ARRAYIT® Corporation (arrayit.com) and links thereon. All such disclosures were made by another who obtained the subject matter disclosed directly or indirectly from the inventor of the present application.
SOMETHING FUN THROWN IN: “ISRC Grant: Purchase Anti-DNA Antibodies as Probes to Prove Validity of Next Generation DNA Microarray Prototypes (Exotic DNA Structures): to Launch a Biotechnology Company-NYIT and Arrayit Corporation (NIH-STTR Grant).” https://www.nyit.edu/files/academic_affairs/AA_OSPAR_internal_grants_ISRC-TLT_AwardRecipients_2017.pdf Gagna’s science, which comes as close as possible to recreating the environmental conditions within cells, is sound: He’s already formed a working partnership with Silicon Valley-based manufacturer Arrayit Corp., which has already produced working prototypes.
Gagna is also considering applying for a U.S. Small Business Administration Small Business Technology Transfer (STTR) grant, likely in the $1.5–3 million range. That would be enough funding, he says, to launch a small startup that could market and manufacture the next-gen microarrays.
“If you’re a pharmaceutical company with 50 new chemicals or biologics, you might want to test them out with our microarrays to see if they’re binding with B-DNA, Z-DNA or quadruplex DNA,” he says. “If they are, maybe you can use those new drugs to inhibit gene expression of a disease, and you have your billion-dollar drug. “This is a cutting-edge approach that can save pharmaceutical companies a lot of time and money, which might result in lower drug prices.”
Arrayit Corp., an 800-pound gorilla in the world of microarrays, is on board and would be part of the STTR grant, bringing its high-end manufacturing, software, and marketing expertise into a potential corporate mix.
“The basic research would be done here at NYIT with our students and the large-scale manufacturing would be done by Arrayit,” Gagna notes. “They believe in the product. They want to be part of the grant. They want to be part of the team.”
Gagna is currently formulating a strategy with NYIT administrators on how to proceed. He estimates a best-case scenario of roughly six years to perfect prototypes and of venture capitalization in order to deliver a fully commercialized product with global potential.
“We already have Arrayit Corp, which knows how to sell microarrays, so we don’t have to go out and hire a sales team,” Gagna says. “And we’re offering researchers two important things: a new approach to studying the structure and function of canonical and exotic DNA and RNA, and a chance to enhance drug-discovery.”
News 
Market Data 
Discover 
